Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens
about
The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humansIgE immunotherapy against cancerTrastuzumab emtansine: mechanisms of action and drug resistanceSerum HER2 level measured by dot blot: a valid and inexpensive assay for monitoring breast cancer progression.Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancerSerum HER 2 extracellular domain level is correlated with tissue HER 2 status in metastatic gastric or gastro-oesophageal junction adenocarcinomaMetabolic characterization of triple negative breast cancer.HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cellsTrastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.Targeting Bcl-2 in Herceptin-Resistant Breast Cancer Cell Lines.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast CancerAlcohol consumption and risk of breast cancer by molecular subtype: Prospective analysis of the nurses' health study after 26 years of follow-up.New developments in the treatment of HER2-positive breast cancerTargeting HER2/neu with a fully human IgE to harness the allergic reaction against cancer cells.Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?Phosphoproteomic analysis identifies activated MET-axis PI3K/AKT and MAPK/ERK in lapatinib-resistant cancer cell line.Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer.Breast cancer and protein biomarkers.Targeting solid tumors with non-pathogenic obligate anaerobic bacteria.The need to examine metastatic tissue at the time of progression of breast cancer: is re-biopsy a necessity or a luxury?Lapatinib resistance in HER2+ cancers: latest findings and new concepts on molecular mechanisms.Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy.Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.Computer Aided Semi-Automated Evaluation of HER2 Immunodetection--A Robust Solution for Supporting the Accuracy of Anti HER2 Therapy.Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers.Alcohol promotes mammary tumor development via the estrogen pathway in estrogen receptor alpha-negative HER2/neu mice.Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer.Is HER2 amplification predictable by digital immunohistochemistry?COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis.EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer.
P2860
Q26992207-550F1F51-4CC0-4847-8E20-9814AF973208Q28081223-60E1C7B9-8799-4758-9C7F-4E9022D3EEF0Q33759627-18C9C45B-1961-4F2E-BEE7-93BE58F724A5Q33886818-4B8703A5-8587-490E-A2B6-0C99DFC30340Q34570753-92DC3A5A-56EC-4FDE-9E18-D2653B9C2A34Q34730478-3ABB6C5F-B6B4-44D4-AB47-AD5BC4091C74Q34967995-C7EA6D2C-E3E4-4410-8B96-9A2B3C9799F1Q35201923-18348CAB-7A3C-4D91-B639-481A115CDDEFQ35559041-156055AB-C735-4127-8493-92DF7F995FF4Q35599629-C0F174C2-F6BB-4485-89B2-30FDA8CEB856Q36440214-7F63A2BD-1ED7-4436-8BAD-51BAD15A5AC7Q36470717-EE9B4968-62E9-49F6-81BA-A7F76BE99859Q37016382-99468D23-3334-49EA-B248-F3E70E3ECE1EQ37035553-98D1587C-3E09-4A2B-8808-BFA3BA01962CQ37218987-6FD33322-8A38-4E0D-A113-6613D154B579Q37361549-68FEB26F-584C-4D04-B27F-4B14C9797D0FQ37457684-BDF391E3-65A4-4E7C-8EBC-51AB323393B9Q37527713-59F2500A-F6C3-4755-B32B-D0B39CAEFE9AQ37767742-71E0E551-2FAD-40A9-9B5C-3E2B3E553F26Q37807333-4E72D5D1-0B24-4631-B27D-C2AE5EAAFAF9Q38812867-F5ED1CA5-DD89-4C57-8689-BBCD8838BC27Q39564433-D96CB80E-FC36-4B0F-922B-645EB5AD24F8Q39675983-96C371A4-DEFC-46DD-AF5D-4D38239C121DQ40264759-4D2F05F5-FE1F-481B-AF07-39E3B0088F14Q42362672-4B9ED540-05FE-44C1-9BA0-B482F6F76774Q46350268-704EA6BD-9A0A-459B-890E-8F309AE211B7Q47350013-96BB625A-624F-4A0E-8558-B66FC2295CC6Q50288154-A293A21E-96AE-4138-878D-B3B65900CED1Q51703393-B1A9F9B1-48DA-45C0-84FE-FC51F41C27C3Q55230010-B021C141-2483-4678-80BE-788F630ACF82
P2860
Personalizing HER2-targeted therapy in metastatic breast cancer beyond HER2 status: what we have learned from clinical specimens
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Personalizing HER2-targeted th ...... earned from clinical specimens
@ast
Personalizing HER2-targeted th ...... earned from clinical specimens
@en
type
label
Personalizing HER2-targeted th ...... earned from clinical specimens
@ast
Personalizing HER2-targeted th ...... earned from clinical specimens
@en
prefLabel
Personalizing HER2-targeted th ...... earned from clinical specimens
@ast
Personalizing HER2-targeted th ...... earned from clinical specimens
@en
P2093
P2860
P1476
Personalizing HER2-targeted th ...... earned from clinical specimens
@en
P2093
P2860
P304
P356
10.2174/187569209790112337
P577
2009-12-01T00:00:00Z